research Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor
Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
Search
for
Sort by
Research
930-960 / 1000+ results 
research Faculty Opinions recommendation of A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Dutasteride 0.5mg was found to be more effective than finasteride 1mg in treating male pattern hair loss, with similar side effects.
research Mesotherapy with bicalutamide for female pattern hair loss
Mesotherapy with bicalutamide has limited effectiveness for female hair loss.
research Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor
research Turpentine Ointment for the Treatment of Folliculitis: An Open, Prospective, Randomized, Placebo- and Comparator-Controlled Multicenter Trial
Turpentine ointment is effective and safe for treating folliculitis.
research Clinical use of 5α-reductase inhibitors
Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.
research Hair Loss Associated with Teriflunomide Treatment
Teriflunomide can cause hair thinning.
research Efficacy, safety and tolerability of dutasteride in male patients with male pattern hair Loss
research The Effect of Finasteride on the Expression of Vascular Endothelial Growth Factor and Microvessel Density: A Possible Mechanism for Decreased Prostatic Bleeding in Treated Patients
Finasteride may reduce prostate bleeding by lowering blood vessel growth factor levels and blood vessel density in certain prostate areas.
research Nonsteroidal inhibitors of human type I steroid 5-.alpha.-reductase
New compounds called benzoquinolinones may treat conditions linked to excess DHT.
research 5alpha-reductase inhibitors - a new hope in dermatology?
Finasteride shows promise for treating hair loss and excessive hair growth, but more research is needed to confirm its effectiveness and safety.
research Oral Minoxidil in the Treatment of Hypertensive Crisis
Minoxidil can lower blood pressure effectively and safely in emergencies.
research Dual-phase release finasteride-loaded microspheres for androgenetic alopecia treatment: rapid intervention and sustained control of dihydrotestosterone
A new finasteride treatment may quickly and effectively promote hair regrowth.
research Alopecia secondary to severe discoid lupus responding to anifrolumab
Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
research PSA concentration change in men taking low dose finasteride and dutasteride for male androgenetic alopecia
research Reply to: Oral dutasteride is a first‐line treatment for frontal fibrosing alopecia – There is insufficient evidence to recommend dutasteride as first‐line treatment in frontal fibrosing alopecia
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Enhanced Insights into Frontal Fibrosing Alopecia: Advancements in Pathogenesis Understanding and Management Strategies
Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.
research Effect of Topically Applied Minoxidil on the Survival of Rat Dorsal Skin Flap
Minoxidil applied before and after surgery improves skin flap survival in rats.
research 5-alpha reductase inhibitors use in prostatic disease and beyond
5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
research Three isostructural solvates of finasteride and their solid-state characterization
Three new finasteride solvates found, change forms under different drying conditions.
research Development of finasteride polymer microspheres for systemic application in androgenic alopecia
Finasteride microspheres help reduce hair loss for up to eight weeks with fewer side effects.
research Systemic cyproterone acetate and 5% minoxidil topical in the treatment of female pattern hair loss
Systemic cyproterone acetate and 5% topical minoxidil are effective and safe for treating female pattern hair loss.
research A clinical investigation using reflectance confocal microscopy to evaluate the add-on efficacy of the Shumin treatment instrument combined with doxycycline for rosacea
The Shumin device with doxycycline is more effective for rosacea than red light therapy.
research Effects of finasteride on expression of vascular endothelial growth factor and microvascular density in retina of early diabetic rats
Finasteride reduces VEGF expression and microvascular growth in diabetic rat retinas.
research The boosting effect of minoxidil 0.1% when combined with dutasteride 0.01% and microneedling in the treatment of female pattern hair loss
Combining minoxidil with dutasteride and microneedling is more effective for female pattern hair loss than just dutasteride and microneedling.
research Leflunomide
Leflunomide is effective for rheumatoid arthritis but has significant side effects.
research Daclizumab
Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
research Simultaneous Determination of Quercitrin, Afzelin, Amentoflavone, Hinokiflavone in Rat Plasma by UFLC–MS-MS and Its Application to the Pharmacokinetics of Platycladus orientalis Leaves Extract
Researchers developed a method to measure plant compounds in rat blood and found they are quickly absorbed and eliminated within 36 hours.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.